Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor

Blood Transfusion

Volumn 11, Issue 1, 2013, Pages 94-101

  Milone, Giuseppe ^a   Tripepi, Giovanni ^b   Martino, Massimo ^c   Ancora, Flavia ^a   Bartolozzi, Benedetta ^d   Spadaro, Andrea ^a   Nozzoli, Chiara ^d   La Fauci, Alessia ^a   Amico, Irene ^a   Leotta, Salvatore ^a   Poidomani, Massimo ^a   Irrera, Giuseppe ^c   Iacopino, Pasquale ^c   Saccardi, Riccardo ^d   Guidi, Stefano ^d   Bosi, Alberto ^d  

^a UNIVERSITY OF CATANIA   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

^c BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

CD34+ cells; Cyclophosphamide; PBSC mobilisation

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ADULT; AGED; ARTICLE; BLOOD; BLOOD CELL; BLOOD CELL COUNT; CD34+ CELL; CONCENTRATION RESPONSE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOMA; PRACTICE GUIDELINE; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STEM CELL MOBILIZATION;

ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD34; CYCLOPHOSPHAMIDE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HODGKIN DISEASE; HUMANS; LEUKOCYTE COUNT; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 84872255432     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0004-12     Document Type: Article

References (30)

1. Flomenberg N, Devine SM, DiPersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-74. (Pubitemid 41208607)
2. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-6.
3. Di Persio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of Plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-73.
4. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilise CD34+1 cells from non- Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/ or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331-8. (Pubitemid 351330727)
5. Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of Plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010; 45: 39-47.
6. Hubel K, Fresen MM, Salwender H, et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2011; 46: 1045-52.
7. D'Addio A, Curti A, Worel N et al. The addition of Plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356-63.
8. Papayannopoulou T, Priestley GV, Nakamoto B, et al. Synergistic mobilization of hemopoietic progenitor cells using concurrent β1 and β2 integrin blockade or β2-deficient mice. Blood 2001; 97: 1282-8. (Pubitemid 32183750)
9. Akard LP, Thompson JM, Dugan MJ, et al. Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: enhanced CD34+ cell collections are not necessarily cost-effective. Biol Blood and Marrow Transplantation 1999; 5: 379-85.
10. Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012; 47: 342-51.
11. Attolico I, Pavone V, Ostuni A, et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2012; 18: 241-9.
12. Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells -definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490-9.
13. Wood WA, Whitley JS, Moore et al. Predictability and costs associated with good and poor mobilizers using a combination of VP-16 and G-CSF for peripheral blood stem cell (PBSC) mobilization and collection. Biol Blood Marrow Transplant 2010; 16 (Suppl. 2): S236.
14. Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413-23. (Pubitemid 36241497)
15. Putkonen M, Rauhala A, Pelliniemi TT, Remes K. Sepsis, low platelet nadir at mobilization and previous IFN use predict stem cell mobilisation failure in patients with multiple myeloma. Cytotherapy 2007; 9: 548-54. (Pubitemid 47457006)
16. Zubair AC, Grant R, Wu W, et al. Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion 2008; 48: 1106-14. (Pubitemid 351793480)
17. Costa LJ, Alexander ET, Hogan KR, et al. Development and validation of a decision-making algorithm to guide the use of Plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64-9.
18. Horwitz ME, Chute JP, Gasparetto C, et al. Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration. Bone Marrow Transplant 2011; DOI: 10.1038/bmt.2011.217.
19. Stroncek DF, Clay ME, Herr G, et al. The kinetics of GCSF mobilization of CD34+ cells in healthy people. Transfus Med 1997; 7: 19-24. (Pubitemid 27141041)
20. Grigg AP, Roberts AW, Raunow H, et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-45.
21. Sinha S, Gastineau D, Micalef I, et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2011; 46: 943-9.
22. Abhyankar S, Dejarnette S, Aljitawi O, et al. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 2012; 47: 483-7.
23. Gratama JW, Kraan J, Keeney M, et al. Validation of the single-platform ISHAGE method for CD34(+) hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy 2003; 5: 55-65. (Pubitemid 36382936)
24. Berto P, Pierelli L, Accorsi P, et al. The cost of mobilization and collection of peripheral blood stem cell in multiple myeloma and lymphoma: results from the GITMO and SIDEM survey (submitted).
25. Shaughnessy P, Islas-Ohlmayer M, Murphy J, et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011; 17: 729-36.
26. Meehan KR, Areman EM, Ericson SG, et al. Mobilisation, collection, and processing of autologous peripheral blood stem cells: development of a clinical process with associated costs. Hematother Stem Cell Res 2000; 9: 767-71.
27. Hosing C, Smith V, Rhodes B, et al. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion 2011; 51: 1300-13.
28. Fitoussi O, Perreau V, Boiron JM, et al. comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837-42. (Pubitemid 32496417)
29. Ozsan GH, Micallef IN, Dispenzieri A, et al. Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma. Am J Hematol 2012; 87: 1-4.
30. Chao NJ, Bernard LM, Carrum G, et al. Differences in stem cell collection practices and related outcomes between centers that conduct and do not conduct apheresis on weekends. ASH 2011, Poster 1925.